{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-014069","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2024-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.036371+00:00","generated_at":"2026-06-04T00:56:28.001872+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"RenovoRx raises $11.1M via private placement of shares and warrants; funds Phase III trial into 2026","bullets":["Gross proceeds of ~$11.1M from sale of 7,912,364 shares and warrants at $1.4075 per unit.","Warrants include Series A (5-year, $1.22 strike) and Series B (2-year, $1.22 strike), 150% warrant coverage.","Cash runway extended into 2026; combined with prior $6.1M Jan 2024 financing.","Proceeds fund pivotal Phase III TIGeR-PaC trial through second interim readout (est. late 2024).","Financing also enables expansion of TAMP clinical pipeline into additional cancer indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-014069","json":"https://secwatch.observer/filing/0001493152-24-014069.json","markdown":"https://secwatch.observer/filing/0001493152-24-014069.md","text":"https://secwatch.observer/filing/0001493152-24-014069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000149315224014069/0001493152-24-014069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000149315224014069/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:56:28.001872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"789a4ecca757d037d165de8fca338146aa32eebc","claim":"RenovoRx, Inc. entered into Subscription Agreements with approximately 170 accredited investors (effective 2024-04-04).","evidence_excerpt":"On April 4, 2024, RenovoRx, Inc. (the “Company”) entered into a series of definitive subscription agreements (the “Subscription Agreements”) in connection with a private placement offering by the Company (the “Offering”) to approximately 170 accredited investors (the “Investors”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1574094/000149315224014069/0001493152-24-014069-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"approximately 170 accredited investors"},{"label":"Effective","value":"2024-04-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}